Fig. 5 miR-330-5p suppressed SPRY2 expression to promote HCC growth.
a The proliferation capacity of HepG2anti-miR-330-5p cells with SPRY2 knockdown (HepG2anti-miR-330-5p+shSPRY2) and MHCC97-LmiR-330-5p cells with SPRY2 ectopic expression (MHCC97-LmiR-330-5p+SPRY2) and their control cells was assessed by MTT assay (a), colony formation assay (b), EdU assay (c), and cell cycle assay (d). e The subcutaneous tumor mouse model was used to compare the tumor volume from SPRY2 interfered HepG2anti-miR-330-5p or MHCC97-LmiR-330-5p cells. f The orthotopic HCC mouse model was used and representative bioluminescence images were taken in the eighth week showed that SPRY2 inhibited tumor growth in vivo